Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-23T08:15:06.609Z Has data issue: false hasContentIssue false
  • English
  • Français

The prediction of response in the anxiety disorders

Published online by Cambridge University Press:  18 September 2015

B.R. Slaap ,
I.M. van Vliet ,
H.G.M. Westenberg  and
J.A. den Boer
Get access Rights & Permissions [Opens in a new window]

Summary

In this review the results are discussed on the prediction of response to pharmacotherapy in panic disorder (PD) and social phobia (SP). From the literature it appears that in PD variables indicative of illness severity are predictors of non-response. In our own studies we found that non-responders to pharmacotherapy in PD are characterised by a higher score on the Blood-Injury subscale of the Fear Questionnaire, a higher plasma MHPG and a higher heart rate. In SP non-responders to pharmacotherapy were also characterised by a higher heart rate. They also appeared to have a higher blood pressure. Furthermore non-responders to pharmacotherapy in SP had higher scores on several psychometric scales, indicative of illness severity.

Keywords

Panic disordersocial phobiafluvoxaminebrofaromineprediction of responsePaniekstoornissociale fobiefluvoxaminebrofarominevoorspelling van reactie
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 8 , Issue 4 , December 1996 , pp. 102 - 104
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Joyce, PR, Paykel, ES. Predictors of drug response in depression. Arch gen Psychiat 1989; 46: 89–99.CrossRefGoogle ScholarPubMed
2.Slaap, BR, Boer, JA den, Westenberg, HGM. De voorspelling van non-respons op farmacotherapie bij paniekstoornis; een over-zicht van korte termijn voorspellers. Tijdschr Psychiat 1996; 38: 371–81.Google Scholar
3.Slaap, BR, Boer, JA den, Westenberg, HGM. De voorspelling van non-respons op farmacotherapie bij paniekstoornis; een over-zicht van lange-termijnvoorspellers. [In Press] Tijdschr Psychiat 1996; in druk.Google Scholar
4.Slaap, BR, Vliet, IM van, Westenberg, HGM, Boer, JA den. Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). J Affect Disord 1995; 33:31–8.Google Scholar
5.Slaap, BR, Vliet, IM van, Boer, JA den, Westenberg, HGM. MHPG and heart rate as correlates of non-response to drug therapy in panic disorder patients. Psychopharmacology 1996; in druk.Google Scholar
6.Vliet, IM van, Westenberg, HGM, Boer, JA den. MAO-inhibitors in panic disorder: clinical effects of treatment with brofaromine, a double blind placebo controlled study. Psychopharmacology 1993;112:483–9.Google Scholar
7.Vliet, IM van, Boer, JA den, Westenberg, HGM, Slaap, BR. A double blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J clin Psychopharmacol 1996; in druk.Google ScholarPubMed
8.Reich, J, Goldenberg, I, Goisman, R, Vasile, R, Keller, M. A prospective, follow-along study of the course of social phobia. 2. Testing for basic predictors of course. J nerv ment Dis 1994; 182:297–301.Google Scholar
9.Versiani, M, Mundim, FD, Nardi, AE, Liebowitz, MR. Tranylcypromine in social phobia. J clin Psychopharmacol 1988; 8: 279-83.Google Scholar
10.Slaap, BR, Vliet, IM van, Westenberg, HGM, Boer, JA den. Responders and nonresponders to drug treatment in social phobia: Differences at baseline and prediction of response. J affect Disord 1996; 39: 13–9.CrossRefGoogle ScholarPubMed
11.Vliet, IM van, Boer, JA den, Westenberg, HGM. Psychopharma-cological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992; 2: 21–9.Google Scholar
12.Vliet, IM van, Boer, JA den, Westenberg, HGM. Psychopharma-cological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994; 115:128–34.Google Scholar